Bayer Sees Xarelto Being Profitable In 2014 As New Drugs Deliver
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer’s pharma sales surged in the second quarter, driven by heart drug Xarelto, new ophthalmic Eylea and cancer treatment Stivarga, prompting the German blue chip to raise its sales forecast for medicines this year and assert that its new oral anticoagulant probably will become profitable in 2014.